Harvest Investment Services LLC Buys 36,025 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Harvest Investment Services LLC grew its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 40.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 125,867 shares of the biotechnology company's stock after buying an additional 36,025 shares during the quarter. Harvest Investment Services LLC owned 0.05% of ADMA Biologics worth $2,159,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ADMA. Lord Abbett & CO. LLC bought a new position in ADMA Biologics during the third quarter valued at $61,858,000. Raymond James Financial Inc. purchased a new position in shares of ADMA Biologics in the fourth quarter worth about $19,076,000. EWG Elevate Inc. bought a new stake in shares of ADMA Biologics in the fourth quarter valued at approximately $480,000. Allspring Global Investments Holdings LLC lifted its stake in shares of ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after buying an additional 2,613,482 shares in the last quarter. Finally, Veracity Capital LLC boosted its holdings in ADMA Biologics by 117.0% in the 4th quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock worth $796,000 after buying an additional 25,030 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 2.1 %

Shares of NASDAQ:ADMA traded down $0.47 during midday trading on Friday, hitting $21.86. 2,611,436 shares of the stock traded hands, compared to its average volume of 3,644,854. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business's 50 day moving average is $18.80 and its two-hundred day moving average is $18.27. The stock has a market capitalization of $5.19 billion, a PE ratio of 78.07 and a beta of 0.53. ADMA Biologics, Inc. has a one year low of $6.49 and a one year high of $23.64.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.